FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an immunoglobulin single variable domain (hereinafter – ISVD) specifically binding TNFα. A compound and compositions containing the above-mentioned ISVD are also disclosed.
EFFECT: invention is effective for the treatment of inflammatory bowel disease (IBD), irritable bowel syndrome, Crohn’s disease, ulcerative colitis, mucositis, aphthous stomatitis, celiac disease, injury of the digestive tract and/or cancer of the digestive tract.
14 cl, 11 dwg, 16 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| MMP13-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2784069C2 |
| POLYPEPTIDES BINDING TO ADAMTS5, MMP13, AND AGGRECAN | 2018 |
|
RU2786659C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| TNF-α BINDING POLYPEPTIDE AND METHOD FOR TREATMENT OF TNF-α RELATED DISEASES | 2017 |
|
RU2794974C2 |
